Cooperation and conflict in cancer: An evolutionary perspective

  • Jonathan Featherston Department of Molecular Medicine and Haematology, University of the Witwatersrand, Johannesburg National Health Laboratory Services, Johannesburg
  • Pierre M. Durand Department of Molecular Medicine and Haematology, University of the Witwatersrand, Johannesburg National Health Laboratory Services, Johannesburg
Keywords: cancer, evolutionary transitions, multilevel selection, mobile genetic elements

Abstract

Evolutionary approaches to carcinogenesis have gained prominence in the literature and enhanced our understanding of cancer. However, an appreciation of neoplasia in the context of evolutionary transitions, particularly the transition from independent genes to a fully integrated genome, is largely absent. In the gene–genome evolutionary transition, mobile genetic elements (MGEs) can be studied as the extant exemplars of selfish autonomous lower-level units that cooperated to form a higher-level, functionally integrated genome. Here, we discuss levels of selection in cancer cells. In particular, we examine the tension between gene and genome units of selection by examining the expression profiles of MGE domains in an array of human cancers. Overall, across diverse cancers, there is an aberrant expression of several families of mobile elements, including the most common MGE in the human genome, retrotransposon LINE 1. These results indicate an alternative life-history strategy for MGEs in the cancers studied. Whether the aberrant expression is the cause or effect of tumourigenesis is unknown, although some evidence suggests that dysregulation of MGEs can play a role in cancer origin and progression. These data are interpreted in combination with phylostratigraphic reports correlating the origin of cancer genes with multicellularity and other potential increases in complexity in cancer cell populations. Cooperation and conflict between individuals at the gene, genome and cell level provide an evolutionary medicine perspective of cancer that enhances our understanding of disease pathogenesis and treatment.

Author Biographies

Jonathan Featherston, Department of Molecular Medicine and Haematology, University of the Witwatersrand, Johannesburg National Health Laboratory Services, Johannesburg
Medical Scientist within the NHLS and PhD student (under Dr Pierre Durand) at the University of Witwatersrand. In both capacities I am under the Department of Molecular Medicine and Haematology.
Pierre M. Durand, Department of Molecular Medicine and Haematology, University of the Witwatersrand, Johannesburg National Health Laboratory Services, Johannesburg
Head of Evolutionary Medicine Unit within the Department of Molecular Medicine and Haematology. Current position as a consultant pathologist within the NHLS.
Published
2012-09-04